Venture capital

China-US biotech startup raises money for flu drug

Lilly Asia Ventures, Oceanpine Capital, Matrix Partners China are betting on Ansun BioPharma to kill the virus on your respiratory tract.
October 14, 2019

China-US based biotech company Ansun BioPharma raised $80 million in its series B funding round to support the phase three clinical trial for its newly-developed medication, the company said on Monday.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Related Articles

A plum position for fashion retail

The e-commerce platform for second-hand fashion products has raised $20 million to help it sell high-end luxury on the cheap.
August 29, 2019

Hong Kong travel unicorn targets Japanese market

Ahead of the 2020 Tokyo Olympics, Asia’s largest in-destination travel services booking platform has raised a record follow on Series D funding led by SoftBank Vision Fund.
April 10, 2019